The mechanisms of action of vincristine sulfate remain under investigation. The mechanism of action of vincristine sulfate has been related to the inhibition of microtubule formation in mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage.

VinCRIStine Sulfate is indicated for Acute leukemia used in combination therapy for:

• Hodgkin's disease
• Non-Hodgkin's lymphomas
• Rhabdomyosarcoma
• Neuroblastoma
• Wilms’ tumor

The usual dose of Vincristine Sulfate Injection, USP for pediatric patients is 1.5–2 mg/m2. For pediatric patients weighing 10 kg or less, the starting dose should be 0.05 mg/kg, administered once a week. The usual dose of Vincristine Sulfate Injection, USP for adults is 1.4 mg/m2. A 50% reduction in the dose of Vincristine Sulfate Injection, USP is recommended for patients having a direct serum bilirubin value above 3 mg/100 mL.

Hair loss, constipation, neuromuscular issues (e.g., paresthesia, neuritic pain).

Severe/Serious

• Neurotoxicity: Peripheral neuropathy, cranial nerve palsies, vocal cord paralysis.

• GI: Paralytic ileus, necrosis, ulceration.

• Pulmonary: Acute respiratory distress.

• Cardiovascular: Hypertension, hypotension, risk of myocardial infarction with prior mediastinal radiation.

• Other: Syndrome of inappropriate antidiuretic hormone secretion (SIADH), myelosuppression, hepatic veno-occlusive disease.

Contraindicated in patients with Charcot-Marie-Tooth syndrome.

Vincristine sulfate can cause fetal harm when administered to a pregnant woman.

Acute uric acid nephropathy, which may occur after the administration of oncolytic agents, has also been reported with vincristine sulfate. In the presence of leukopenia or a complicating infection, administration of the next dose of Vincristine Sulfate Injection warrants careful consideration.

Avoid use with strong inhibitors/inducers like itraconazole or St. John’s Wort.